The estimated Net Worth of Chandra Vargeese is at least $2.56 Milión dollars as of 22 July 2024. Chandra Vargeese owns over 68,210 units of Wave Life Sciences stock worth over $1,091,860 and over the last 8 years he sold WVE stock worth over $228,625. In addition, he makes $1,239,520 as Senior Vice President a Head of Drug Discovery at Wave Life Sciences.
Chandra has made over 12 trades of the Wave Life Sciences stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 68,210 units of WVE stock worth $169,161 on 22 July 2024.
The largest trade he's ever made was exercising 68,210 units of Wave Life Sciences stock on 22 July 2024 worth over $169,161. On average, Chandra trades about 6,772 units every 128 days since 2016. As of 22 July 2024 he still owns at least 185,061 units of Wave Life Sciences stock.
You can see the complete history of Chandra Vargeese stock trades at the bottom of the page.
Dr. Chandra Vargeese Ph.D. serves as Senior Vice President, Head of Drug Discovery of the Company. serves as Senior Vice President, Head of Drug Discovery of the Company. serves as Senior Vice President, Head of Drug Discovery of the Company. Before joining us, Dr. Vargeese served as Novartis’ Executive Director and Head of RNA Chemistry and Delivery, a position she held from 2008 to 2014. Prior to joining Novartis, Dr. Vargeese led siRNA delivery in the RNA Therapeutics division at Merck & Co., where she served as Senior Director and Head of RNA Chemistry and Delivery. Dr. Vargeese joined Merck through its acquisition of Sirna Therapeutics, where she was Vice President of Chemistry. Before Sirna, Dr. Vargeese served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is the co-inventor of Macugen (pegaptanib), an approved therapy for treating wet AMD. Dr. Vargeese earned a Ph.D. in Organic Chemistry at the Indian Institute of Science, Bangalore, India and completed post-doctoral work at the University of Rhode Island.
As the Senior Vice President a Head of Drug Discovery of Wave Life Sciences, the total compensation of Chandra Vargeese at Wave Life Sciences is $1,239,520. There are 3 executives at Wave Life Sciences getting paid more, with Paul Bolno having the highest compensation of $3,581,530.
Chandra Vargeese is 58, he's been the Senior Vice President a Head of Drug Discovery of Wave Life Sciences since 2014. There are 4 older and 14 younger executives at Wave Life Sciences. The oldest executive at Wave Life Sciences Ltd. is Koji Miura, 71, who is the Independent Director.
Chandra's mailing address filed with the SEC is C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE, MA, 02138.
Over the last 9 years, insiders at Wave Life Sciences have traded over $19,158,839 worth of Wave Life Sciences stock and bought 18,619,108 units worth $128,204,225 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Ra ... a Capital Management, Llc Kol.... On average, Wave Life Sciences executives and independent directors trade stock every 43 days with the average trade being worth of $1,569,819. The most recent stock trade was executed by Paul Bolno on 21 August 2024, trading 48,366 units of WVE stock currently worth $279,555.
wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.
Wave Life Sciences executives and other stock owners filed with the SEC include: